AVM Biotechnology – a clinical stage company founded in 2008 – is advancing AVM0703 in an adaptive design expansion cohort clinical trial in patients with Non-Hodgkin’s Lymphoma/Leukemia. Led by a strong executive leadership team and global scientific advisory board, the company is planning for a direct commercial launch as well as developing its lead drug, AVM0703, as an ‘off-the-shelf’ cell therapy product with broad applications in cancer, autoimmune diseases, and other indications.
oncologygamma delta NKT
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.